Trump's Medical Report Excludes Hair-Loss Medication, Prompting Health Transparency Concerns

Donald Trump has removed finasteride, a hair-loss treatment sold under the brand name Propecia, from his publicly disclosed medications. This change has been noted since he resumed office in January 2026, with the latest medical report released on June 4, 2026, not listing the drug. Trump's aides have not provided an explanation for its absence or confirmed whether he is still taking it. The White House stated that the report reflects all clinically relevant medications and that no significant health conditions were omitted. Robert Klitzman, a psychiatrist at Columbia University, expressed concerns regarding the lack of transparency about the president's health, particularly regarding the potential side effects of finasteride, which include depression and sexual dysfunction. Trump's health disclosures have faced scrutiny in the past, including his handling of COVID-19 and his medical evaluations. The latest report claims Trump is in 'excellent health' but has been criticized for lacking detailed supporting data.